Cargando…
Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases
The main purpose of the present study is to develop an immunosafe fibrin membrane obtained by plasma rich in growth factors technology (is-mPRGF) with improved mechanical properties that could be applied in patients with inflammatory ocular diseases. Blood was drawn from three healthy donors and cen...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598884/ https://www.ncbi.nlm.nih.gov/pubmed/36290475 http://dx.doi.org/10.3390/bioengineering9100508 |
_version_ | 1784816458586390528 |
---|---|
author | Anitua, Eduardo de la Fuente, María Merayo-Lloves, Jesús Muruzabal, Francisco |
author_facet | Anitua, Eduardo de la Fuente, María Merayo-Lloves, Jesús Muruzabal, Francisco |
author_sort | Anitua, Eduardo |
collection | PubMed |
description | The main purpose of the present study is to develop an immunosafe fibrin membrane obtained by plasma rich in growth factors technology (is-mPRGF) with improved mechanical properties that could be applied in patients with inflammatory ocular diseases. Blood was drawn from three healthy donors and centrifuged, and the collected PRGF was activated and distributed into two groups: (i) mPRGF: a PRGF membrane maintained at 37 °C for 30 min; (ii) IS5+30: mPRGF incubated at 37 °C for 5 min and then incubated at 56 °C for 30 min. The content of both membranes was analyzed for several growth factors such as IgE and the complement activation, as well as biological activity on different ocular surface cells. Furthermore, the physical and mechanical characterizations were also evaluated. IS5+30 completely reduced the complement activity and decreased the IgE while preserving the concentration of the main growth factors. IS5+30 induced similar biological activity regarding mPRGF on the different ocular surface cells analyzed. Furthermore, no significant differences in release kinetics or fibrin degradation were observed between both membranes. Summarizing, IS5+30 totally reduces complement activity while preserving the concentration of most growth factors and their biological activity. Furthermore, the physical and mechanical properties of the fibrin membrane are preserved after heat inactivation. |
format | Online Article Text |
id | pubmed-9598884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95988842022-10-27 Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases Anitua, Eduardo de la Fuente, María Merayo-Lloves, Jesús Muruzabal, Francisco Bioengineering (Basel) Article The main purpose of the present study is to develop an immunosafe fibrin membrane obtained by plasma rich in growth factors technology (is-mPRGF) with improved mechanical properties that could be applied in patients with inflammatory ocular diseases. Blood was drawn from three healthy donors and centrifuged, and the collected PRGF was activated and distributed into two groups: (i) mPRGF: a PRGF membrane maintained at 37 °C for 30 min; (ii) IS5+30: mPRGF incubated at 37 °C for 5 min and then incubated at 56 °C for 30 min. The content of both membranes was analyzed for several growth factors such as IgE and the complement activation, as well as biological activity on different ocular surface cells. Furthermore, the physical and mechanical characterizations were also evaluated. IS5+30 completely reduced the complement activity and decreased the IgE while preserving the concentration of the main growth factors. IS5+30 induced similar biological activity regarding mPRGF on the different ocular surface cells analyzed. Furthermore, no significant differences in release kinetics or fibrin degradation were observed between both membranes. Summarizing, IS5+30 totally reduces complement activity while preserving the concentration of most growth factors and their biological activity. Furthermore, the physical and mechanical properties of the fibrin membrane are preserved after heat inactivation. MDPI 2022-09-27 /pmc/articles/PMC9598884/ /pubmed/36290475 http://dx.doi.org/10.3390/bioengineering9100508 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Anitua, Eduardo de la Fuente, María Merayo-Lloves, Jesús Muruzabal, Francisco Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases |
title | Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases |
title_full | Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases |
title_fullStr | Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases |
title_full_unstemmed | Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases |
title_short | Optimization of a Plasma Rich in Growth Factors Membrane for the Treatment of Inflammatory Ocular Diseases |
title_sort | optimization of a plasma rich in growth factors membrane for the treatment of inflammatory ocular diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598884/ https://www.ncbi.nlm.nih.gov/pubmed/36290475 http://dx.doi.org/10.3390/bioengineering9100508 |
work_keys_str_mv | AT anituaeduardo optimizationofaplasmarichingrowthfactorsmembraneforthetreatmentofinflammatoryoculardiseases AT delafuentemaria optimizationofaplasmarichingrowthfactorsmembraneforthetreatmentofinflammatoryoculardiseases AT merayollovesjesus optimizationofaplasmarichingrowthfactorsmembraneforthetreatmentofinflammatoryoculardiseases AT muruzabalfrancisco optimizationofaplasmarichingrowthfactorsmembraneforthetreatmentofinflammatoryoculardiseases |